Comparative Pharmacology
Head-to-head clinical analysis: ALYFTREK versus HEXADROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALYFTREK versus HEXADROL.
ALYFTREK vs HEXADROL
Head-to-head clinical comparison of therapeutic indices and safety profiles.
ALYFTREK (vutrisiran) is a transthyretin-directed small interfering RNA that binds to the 3' untranslated region of mutant and wild-type TTR mRNA, leading to its degradation via RNA interference, thereby reducing hepatic production of TTR protein and decreasing amyloid deposition.
Synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to regulation of gene expression and suppression of inflammatory cytokines, immune response, and adrenal function.
Treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults
FDA-approved: allergic conditions, dermatologic diseases, endocrine disorders, gastrointestinal diseases, hematologic disorders, neoplastic diseases, nervous system disorders, ophthalmic diseases, renal diseases, respiratory diseases, rheumatic disordersOff-label: prevention of respiratory distress syndrome in preterm infants, treatment of COVID-19 (dexamethasone)
For patients with cystic fibrosis (CF) who are heterozygous for the F508del mutation in the CFTR gene and a minimal function mutation (F/MF genotypes): elexacaftor 200 mg/tezacaftor 100 mg/ivacaftor 125 mg orally, two tablets in the morning, and ivacaftor 150 mg orally, one tablet in the evening, approximately 12 hours apart. For patients homozygous for F508del (F/F genotypes): elexacaftor 200 mg/tezacaftor 100 mg/ivacaftor 125 mg orally, two tablets in the morning, and ivacaftor 150 mg orally, one tablet in the evening.
Adult: 0.75-9 mg/day orally in divided doses every 6-12 hours; IV/IM: initial 0.5-9 mg/day in divided doses every 6-12 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 72 hours after single dose and extends to ~120 hours at steady state due to dose-dependent elimination; allows once-weekly dosing.
Terminal elimination half-life: 36-54 hours; prolonged in hepatic impairment (up to 72 hours) due to reduced clearance.
Metabolized via nuclease-mediated degradation to oligonucleotides of various lengths.
Primarily hepatic via CYP3A4; metabolites are excreted in urine.
Primarily hepatic metabolism, with ~70% excreted in feces as metabolites and ~20% in urine (mostly as metabolites). <1% excreted unchanged in urine.
Primarily renal: ~65-80% as unchanged drug and metabolites via glomerular filtration, with tubular reabsorption; minor biliary/fecal (5-10%).
>99% bound, primarily to albumin and α1-acid glycoprotein.
70-80% bound; primary binding to corticosteroid-binding globulin (CBG) and albumin.
Distribution volume approximately 10–12 L/kg, suggesting extensive extravascular distribution into tissues.
0.8-1.0 L/kg; indicates extensive tissue distribution, including crossing the blood-brain barrier.
Oral bioavailability is approximately 70–80% when taken with food; reduced by ~40% under fasted conditions.
Oral: 80-90% (well absorbed); IM: 100% (systemic).
No dose adjustment is required for mild to moderate renal impairment (eGFR ≥30 mL/min/1.73 m²). For severe renal impairment (eGFR <30 mL/min/1.73 m²) or end-stage renal disease, use is not recommended due to limited data.
No specific GFR-based dose adjustments required; use with caution in severe renal impairment (eGFR <30 mL/min).
Child-Pugh Class A (mild): No dose adjustment. Child-Pugh Class B (moderate): Initiate with reduced dose: in the morning, two tablets of elexacaftor 150 mg/tezacaftor 75 mg/ivacaftor 94 mg (instead of 200/100/125 mg), and in the evening, one tablet of ivacaftor 75 mg (instead of 150 mg). Child-Pugh Class C (severe): Not recommended.
Child-Pugh A: no adjustment. Child-Pugh B/C: reduce dose by 50% or use lowest effective dose.
Approved for children aged 6 years and older weighing ≥30 kg: same adult dosing. For children aged 6 to <12 years weighing <30 kg: morning dose: two tablets of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg; evening dose: one tablet of ivacaftor 75 mg. For children aged 2 to <6 years weighing ≥14 kg: morning dose: two packets of oral granules (elexacaftor 80 mg/tezacaftor 40 mg/ivacaftor 60 mg per packet); evening dose: one packet of oral granules (ivacaftor 59.5 mg per packet).
0.08-0.3 mg/kg/day or 2.5-10 mg/m²/day orally in divided doses every 6-12 hours; IV/IM: 0.08-0.3 mg/kg/day in divided doses every 12-24 hours.
No specific dose adjustment is recommended for elderly patients (≥65 years). Pharmacokinetic data are limited; monitor for adverse effects.
Start at lowest effective dose (e.g., 0.75 mg/day) and titrate slowly; monitor for hyperglycemia, osteoporosis, and infections.
No black box warnings.
None
["Reduced serum vitamin A levels: Supplement with recommended daily allowance of vitamin A.","Hypersensitivity reactions including angioedema have occurred; discontinue if severe."]
["Immunosuppression and increased susceptibility to infections","Hypothalamic-pituitary-adrenal axis suppression and adrenal insufficiency with withdrawal","Gastrointestinal perforation (especially in colitis)","Osteoporosis and avascular necrosis","Ocular effects: cataracts, glaucoma","Psychiatric disturbances","Cardiovascular effects: hypertension, fluid retention","Growth suppression in children"]
None.
["Systemic fungal infections","Hypersensitivity to dexamethasone or any component","Administration of live virus vaccines in patients on immunosuppressive doses"]
Data Pending Review
Data Pending Review
No specific food interactions are known with ALYFTREK. However, delayed gastric emptying may be exacerbated by high-fat or high-calorie meals; patients are advised to consume smaller, low-fat meals to improve tolerability. Alcohol may increase the risk of hypoglycemia when combined with insulin secretagogues.
Avoid grapefruit and grapefruit juice as they may increase dexamethasone levels. Limit sodium intake to reduce fluid retention. Maintain adequate calcium and vitamin D intake to counteract bone loss.
Pregnancy Category X. First trimester: High risk of major congenital malformations including craniofacial defects, neural tube defects, and cardiac anomalies. Second and third trimesters: Increased risk of spontaneous abortion, intrauterine growth restriction, and fetal death. Human data show teratogenicity at therapeutic doses.
First trimester: Increased risk of cleft palate (odds ratio 3.6), orofacial clefts; second/third trimester: Fetal adrenal suppression, intrauterine growth restriction, oligohydramnios with prolonged high-dose use.
Contraindicated during breastfeeding. No M/P ratio available; drug is excreted into breast milk and may cause serious adverse reactions in nursing infants due to known toxicity.
Enters breast milk; M/P ratio ~0.3; low concentrations; considered compatible with breastfeeding but monitor infant for adrenal suppression if high maternal doses.
No established safe dose; contraindicated in pregnancy. If inadvertent exposure occurs, immediate discontinuation is recommended. Pharmacokinetic changes in pregnancy may increase clearance, but no dose adjustments are applicable due to contraindication.
No standard dose adjustment; use lowest effective dose; increased clearance in pregnancy may require higher doses for anti-inflammatory effect; taper if chronic use to prevent adrenal crisis.
Category C
Category C
ALYFTREK (tirzepatide) is a dual GIP and GLP-1 receptor agonist. It is administered once weekly subcutaneously. Rapid dose escalation may worsen gastrointestinal tolerability; follow the titration schedule strictly. Consider holding the dose prior to procedures requiring prolonged fasting. Monitor for signs of pancreatitis, gallbladder disease, and hypoglycemia, especially when used with sulfonylureas or insulin. In patients with renal impairment, monitor for gastrointestinal adverse effects leading to dehydration. Not recommended in patients with severe gastrointestinal disease (e.g., gastroparesis).
HEXADROL (dexamethasone) has a long duration of action (36-54 hours), allowing for once-daily dosing. Use with caution in patients with diabetes, as it can cause hyperglycemia. For cerebral edema, rapid onset of action is beneficial; high doses may cause psychosis. Do not withdraw abruptly after prolonged use; taper to avoid adrenal insufficiency.
Inject ALYFTREK once weekly on the same day. If a dose is missed and 4 or more days remain until the next scheduled dose, administer it as soon as possible; if less than 4 days, skip the missed dose.Store in the refrigerator (2°C to 8°C). After first use, can be stored at room temperature (up to 30°C) for up to 21 days.Common side effects include nausea, diarrhea, vomiting, constipation, and abdominal pain; these often improve over time.Seek medical attention if you experience severe abdominal pain (possible pancreatitis) or signs of gallbladder issues (upper right abdominal pain, jaundice).Inform your healthcare provider if you are taking sulfonylureas or insulin; dose adjustments may be needed to prevent hypoglycemia.Avoid skipping meals or drastically reducing fluid intake, as this may worsen gastrointestinal symptoms.
Take exactly as prescribed; do not stop suddenly without consulting your doctor.Report any unusual weight gain, swelling, or changes in vision immediately.Avoid live vaccines while on this medication.May cause increased appetite, insomnia, or mood changes; discuss if severe.Wear a medical alert ID if using long-term.